{ "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583", "docSlug": "f06b0b5d2079", "documentTitle": "Soleno Therapeutics (SLNO)", "authorId": "58_Scorpion_Capital", "authorName": "Scorpion Capital", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2025-08-15 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 313, "pageCount": 415, "prevPage": 312, "nextPage": 314, "slideType": "expose_contradiction", "function": "expose_contradiction", "density": "dense", "nDataPoints": 0, "notes": "The slide uses a Q&A format to highlight the expert's skepticism about the company's reporting practices.", "elementsJson": [ "paragraph", "quote_block", "footnote" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/313", "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583", "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-313", "components": [ { "bbox": null, "kind": "callout", "text": "Lack of reporting on insulin resistance is highly troubling – “very odd”; “are they hiding something”; “really weird”", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-64ce-7561-b2b0-7ffd18d2fc9f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.86, "x": 0.07, "y": 0.37 }, "kind": "paragraph", "text": "Lack of reporting on insulin resistance is highly troubling – “very odd”; “are they hiding something”; “really weird”", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "3c731565-7d81-4f73-be47-49de83ef293d", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.86, "x": 0.07, "y": 0.49 }, "kind": "paragraph", "text": "Q: “You’re saying that if the drug works, it should show an improvement in those biomarkers?”", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "9efc3f52-a162-43f7-a7b6-775a0ef2363d", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.15, "w": 0.86, "x": 0.07, "y": 0.51 }, "kind": "quote", "text": "A: “Yeah, or at least no change, no worsening. One would expect to see — supposedly leptin levels come way down, suggesting the fat biology is changing and there’s some reduction in fat mass and improvement in muscle. I think it was more improvement in muscle mass, if I remember rightly, than the fact that came down. But then the leptin really went down. That could be central control of peripheral fat metabolism through some pathway. But I would like to have seen the effect on insulin resistance. They just didn’t report those, and that was very odd to me. Then that seemed to again, are they hiding something? It’s really weird. It’s such an obvious thing. That a major reviewer didn’t ask for that to be done. So, that’s very odd. I don’t quite know what was going on there.” –Trial investigator; endocrinologist; one of the most published authorities on PWS and hyperphagia", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "3d6bf7c4-9388-43db-9718-315cf9476542", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.86, "x": 0.07, "y": 0.41 }, "kind": "quote", "text": "A: “Insulin resistance should be improving because insulin levels do come down. But I’m just really surprised they haven’t reported either the HOMA-B, the insulin production rate and the insulin resistance. I don’t know why they haven’t reported that in either of the papers that I’ve seen.”", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "dee9fd8a-ffa4-4823-b80a-f5e3483ec4e3", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "“Insulin resistance should be improving because insulin levels come down. But I’m just really surprised they haven’t reported either the HOMA-B, the insulin production rate and the insulin resistance. I don’t know why they haven’t reported that in either of the papers that I’ve seen.” — Trial investigator; endocrinologist; one of the most published authorities on PWS and hyperphagia", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd953-64ce-7561-b2b0-81fc79cc4179", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.3, "x": 0.07, "y": 0.95 }, "kind": "source-note", "text": "Source: Scorpion Capital consultation calls with experts", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "7052a735-a186-4d3c-967d-05abc79c570a", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.12, "w": 0.86, "x": 0.07, "y": 0.07 }, "kind": "title", "text": "Trial investigator #4 zeroed in on the lack of reporting on insulin resistance as particularly troubling", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "7bea9e25-3698-41ab-895f-c9d398a9f469", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [ { "name": "fraud-exposure", "slug": null, "matchId": "6ffcf23d-fc71-4af7-8a91-0e820b399dc5", "evidence": "The slide explicitly frames the omission of data as a potential act of hiding information, characteristic of fraud exposure.", "confidence": 0.9 } ], "arcBeats": [], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }